Pharmaceutical composition comprising 40-O-(2-hydroxyethyl)rapamycin for use as a sole active ingredient in the treatment of solid lung or bronchus tumours other than lymphatic cancer

摘要

40-O-(2-hydroxyethyl)rapamycin (everolimus) is proposed for use as a sole active ingredient in the treatment of solid lung or bronchus tumours other than lymphatic cancer. Disclosed is antiproliferative and antiangiogenic activity of 40-O-(2-hydroxyethyl)rapamycin when used in combination with another active agent or alone.